Abnormally phosphorylated Tau protein, the major component of neurofibrillary tangles, is critical in the pathogenesis of Alzheimer's disease and related Tauopathies. We used Drosophila to examine the role of key disease-associated phosphorylation sites on Tau-mediated neurotoxicity. We present evidence that the late-appearing phosphorylation on Ser 238 rather than hyperphosphorylation per se is essential for Tau toxicity underlying premature mortality in adult flies. This site is also occupied at the time of neurodegeneration onset in a mouse Tauopathy model and in damaged brain areas of confirmed Tauopathy patients, suggesting a similar critical role on Tau toxicity in humans. In contrast, occupation of Ser 262 is necessary for Tau-dependent learning deficits in adult Drosophila. Significantly, occupation of Ser 262 precedes and is required for Ser 238 phosphorylation, and these temporally distinct phosphorylations likely reflect conformational changes. Because sequential occupation of Ser 262 and Ser 238 is required for the progression from Tau-mediated learning deficits to premature mortality in Drosophila, they may also play similar roles in the escalating symptom severity in Tauopathy patients, congruent with their presence in damaged regions of their brains.
Introduction
Tau is a neuronal microtubule-associated protein thought to promote cytoskeletal stability and axonal transport among its other established and proposed functions (1, 2) . In the adult human central nervous system (CNS), alternative splicing of primary transcripts from the single tau gene yields six different isoforms lacking or incorporating one or two N-terminal inserts (0N, 1N and 2N) and three or four microtubule-binding repeats (MBRs), designated 3R or 4R, respectively (3) . The ratio of 3R-to-4R isoforms is about one in normal brains, with 4R exhibiting higher affinity for microtubules than 3R in vitro (4) . Conversely, the amino-terminal domain is thought important for interaction with cellular membranes (5, 6 ) and the nucleus (7) .
The most prominent feature of Tau is its extensive phosphorylation on 84 confirmed and putative sites (8) . Excessive phosphorylation is reported to decrease Tau affinity for microtubules and hence lower their stability (9) , but how it may influence other Tau function (s) is not yet fully understood. Extensive Tau phosphorylation has been reported in developing rather than mature neurons (10) , suggesting a physiological, potentially regulatory role for this process. In contrast, Tauopathies typically involve changes in Tau phosphorylation in mature neurons consequent to either an increase in the number of sites phosphorylated in the same Tau molecule or an increase in the fraction of Tau molecules phosphorylated at a given site (11) . Phosphorylation sites occupied in normal and Tauopathy samples, albeit more extensively in the later, have been revealed by comparative analyses (8, 12) . In addition, sites not occupied physiologically, but phosphorylated on Tau from patient samples are known as 'disease-associated' phosphoepitopes and are recognized by specific monoclonal antibodies often used as disease biomarkers (13) . The mechanism(s) that trigger(s) increasing phosphorylation (hyperphosphorylation), at physiological and non-physiological epitopes, is currently largely unknown. It is also still unclear whether phosphorylation per se, or occupation of particular sites, renders Tau pathogenic and which sites are essential for initiation, maintenance and evolution of pathology. Identification of such pathogenesis-linked phosphorylation sites is pivotal to our understanding of Tau-dependent neuronal toxicity. However, comparative studies aimed at identification of such phosphoepitopes (8, 12) do not allow functional interrogation, or systematic investigation of the order and potential functional consequences of their appearance. Ordered phosphoepitope appearance is likely critical to understanding pathogenesis because it may reflect and be predictive of the escalating dysfunctions characterizing the various Tauopathies.
We have been investigating the role of particular Tau phosphoepitopes on the development and function of the adult nervous system in the Drosophila Tauopathy model (14) (15) (16) . Drosophila is particularly conducive to temporal resolution of Tau accumulation, its phosphorylations and their consequences, because it affords precise spatiotemporal control of transgene expression (17) and facile generation and analysis of multiple Tau variants harboring amino acid substitutions that block or mimic phosphorylation on single or multiple sites (18, 19) . We reported that wild-type (wt) and mutant Tau proteins are differentially toxic to developing mushroom body (MB) neurons and identified two novel phosphorylation sites essential for this toxicity, Ser 238 just proximal to and Thr
245
, the second residue of the first MBR (15) . The MBs are bilateral neuronal assemblies essential for olfactory learning and memory (20) . Blocking Ser 238 and Thr 245 phosphorylation resulted in structurally normal, but profoundly dysfunctional MBs (15) . This suggests that Tau toxicity to the developing MBs is separable from that resulting in dysfunction of terminally differentiated adult neurons underlying the learning deficits presented by human Tau-expressing flies (15, 21, 22) . Here, we use a collection of Tau variant proteins with distinct 'disease-associated' phosphorylation sites and recently identified (15) novel ones, to systematically investigate their role in Tau-mediated toxicity underlying dysfunction in the post-developmental adult fly CNS. Using a specific antibody against the functionally identified novel phospho-Ser 238 , we also test the hypothesis that this site is essential for toxicity in flies and humans, and examine its functional relationship with the other 'disease-associated' phosphorylation sites.
Results
Wt Tau and FTDP-17-associated mutants are phosphorylated at Ser
238
The toxicity-ameliorating effect of mutating Ser 238 and Thr 245 to Ala in the STA mutant (15) suggests that they are novel essential sites for Tau-dependent pathogenesis. Because Thr 245 is reported constitutively phosphorylated in normal brains (23) (24) (25) , we focused initially on Ser 238 using a novel antibody we generated (antipSer238). The antibody is specific against phosphorylated Ser 238 because it was affinity purified over the phosphopeptide used to generate it; the epitope was eliminated after phosphatase treatment (Supplementary Material, Fig. S1 ) and is absent (Fig. 1A ) from the transgenic Tau protein with Ser 238 converted to the nonphosphorylatable alanine in the STA mutant (15) . We investigated Ser 238 occupation in lysates of adult heads expressing pan-neuronally wt Tau isoforms (0N4R and 2N4R), frontotemporal dementia and parkinsonism linked to chromosome-17
(FTDP-17)-linked mutants (R406W and V337M) and the benign variants 2NS2A (26) and RWS2A (27) . In 2NS2A and RWS2A, the Par- 1-targeted Ser  262 and Ser  356 on 2N4R and R406W, respectively, have been changed to Ala and their expression spares the MBs structurally and functionally (15, 22) . In accord with the hypothesized essential role of Ser  238 for Tau toxicity, all but the benign   Tau variants 2NS2A, RWS2A and 2N4R-STA (Ser  238 to Ala variant) were phosphorylated at this site (Fig. 1A) . Therefore, Tau isoforms associated with MB toxicity in Drosophila are differentially phosphorylated on Ser
.
Ser 238 is occupied in toxic Tau variants
To confirm that Ser 238 phosphorylation correlates with toxicity, and to identify additional potential sites involved in this phenotype, we used a series of 0N4R variants where phosphorylation of serines and threonines within 'disease-associated' epitopes was blocked by alanine substitution. These sites are located either amino-terminally (T111A/T153A, T175A/T181A, S199A/T217A, S202A/T205A, T21A, S214A and T231A/S235A), or carboxyterminally (S396A/S404A and S422A), of the MBR and Tau variants bearing them are reported to remain toxic in the retina (18) . A single variant is located in the MBR and involves the Par-1 site Ser 262 (28) .
To determine the toxic potential of these variants, initially we asked whether their continuous pan-neuronal expression from the early embryo onwards under Elav-Gal4 affected the development of the MBs as described before (15) . We were unable to assess T231A/S235A and all variants with changes located downstream of the MBR, because they precipitated embryonic lethality (Fig. 3H ), even at low Tau expression levels (flies raised at 18°C). All Tau variants with blocked phosphorylation sites amino-terminal to the MBR were as toxic to the MBs as wt 0N4R, yielding near complete elimination of dendritic (Fig. 1B) and axonal structures (Supplementary Material, Fig. S2 ). In contrast, the S262A mutation within the MBR did not affect MB structure in agreement with a previous report (28) . Because the RWS2A and 2NS2A mutations are also benign (22) , the results suggest that Par-1 phosphorylation either of Ser 262 and Ser
356
, or at least the former of the two, is required for Tau toxicity to the developing MBs, as also reported for toxicity to the retina (26) (27) (28) .
Occupation of particular epitopes has been reported to gate phosphorylation at distant sites (27) (Fig. 1C ). Control and variant proteins with exception of S262A accumulated at comparable levels as indicated by the phosphorylation-independent antibody T46 ( Fig. 1C -Tau) and quantified in Figure 1D . S262A accumulation was reduced by ∼50% compared with 0N4R and other variants ( Fig. 1D and E (blots) and held arbitrarily to 1. The mean ratio of the level of total Tau from the mutant transgenes to that of Syx was similarly estimated from lysates run in the same blots as those used to estimate the 0N4R ratio and plotted along with the standard error of the mean (±SEM). The levels of 0N4R were significantly lower than those of the S214A variant (P = 0.005, Dunnett's test) and highly significantly higher (P < 0.0001, Dunnett's test) than those of S262A. (E) Quantification of the level of occupation at the indicated phosphorylation sites in the S262A variant, which was calculated relative to Syx as detailed above. The mean ± SEM from six independent experiments is shown. The level of AT100 occupation was reduced (P = 0.008, Dunnett's test) relative to the total amount of S262A protein, while the reduction in Ser 238 occupation was dramatic (P < 0.0001, Dunnett's test). As expected, Ser 262 was not occupied in this variant. (F) Quantification of the level of occupation at the indicated phosphorylation sites in the T212A variant, which was calculated relative to Syx as detailed above. The mean ± SEM from six independent experiments is shown. As expected, Thr 212 and consequently AT100 were not occupied in this variant, but the occupation levels in the other sites surveyed were not different than the mean total amount of protein in the lysates. Fig. S3 ).
Given that the S262A variant accumulated at 50% of 0N4R (Fig. 1D) , we quantified several experiments to determine the effect of this mutation on other phosphorylation sites with precision. The results shown in Figure 1E indicate that the PHF and pT212 epitopes were occupied as much as in other variants (for instance in T212A shown as control in Fig. 1F ), relative to the total amount of S262A protein present. Significantly, occupation of Ser 238 is nearly abolished in the S262A variant (Fig. 1E ). Significantly, all variants that precipitated severe MB defects ( Fig. 1B) were phosphorylated at the newly defined pSer 238 epitope (Fig. 1C) , strongly supporting the hypothesis that this phosphorylation is linked to toxicity. In agreement, Ser 238 phosphorylation was not apparent in the benign 2NS2A and RWS2A proteins ( Fig. 1A and (22)), where Ser 262 is changed to Ala.
Temporally ordered Tau phosphorylations and toxicity
Pan-neuronal Tau accumulation in the Drosophila CNS throughout development shortens its adult lifespan due to apparent cumulative neurotoxicity appearing as vacuoles in the adult CNS and peripheral nervous system (30, 31) . Vacuoles indicating neuronal loss have also been reported within the MBs of 45-day-old animals when wt Tau expression was limited to these neurons (21) . Because Tauopathies typically affect the adult post-developmental CNS (32), we focused on the effects of adult-specific accumulation of wt and Tau variant proteins using the TARGET system (17) . Continuous Tau accumulation from the embryonic CNS onwards results in a significantly decreased longevity and has been used a measure of cumulative agedependent neurotoxicity (31, 33) .
To limit Tau accumulation to the adult CNS, we suppressed transgene expression during development with Gal80 ts (17) , induced it in 2-day-old adults by shifting the animals to 30°C and maintained it until the animals expired. As expected, these flies do not exhibit Tau accumulation upon emergence, but present a significant amount of Tau within 24 h post-induction and thereafter ( Fig. 1A -Tau). Importantly, adult-specific 0N4R accumulation resulted in significantly reduced longevity, as nearly 50% of the animals expired around Day 21 (at 30°C) and none survived past Day 30 ( Fig. 2B) . A similar survival profile has been reported on adult-specific expression of the same Tau isoform in glia (34) . In contrast, 50% attrition in controls required at least 5 additional days and the population was completely eliminated by Day 35 ( Gal80 ts /+ (G4; G80>w) heterozygotes and the respective transgene heterozygotes (i.e. w>0N4R). The mean ± SEM are shown for n > 9 for each group. Data were normally distributed and differences were revealed with Dunnett's tests within each group. Significant differences (P < 0.001) between the experimental group and the G4;G80>w controls were uncovered for 0N4R, S199A/T217A, T212A and S214A, but not for S262A (P = 0.242). (F) Western blots assessing occupation of the indicated phosphoepitopes on post-induction Day 12 when learning performance was assessed. Total Tau was revealed with the T46 antibody and Syntaxin was used as the loading control.
(G) Survival curves for animals expressing 0N4R, T212A, S214A and S199A/T217A variants expressed specifically in the adult CNS in comparison with Elav/+; Gal80 ts /+ control heterozygotes (w). The data represent the mean ± SEM from four independent experiments with a total of 300 flies assessed per genotype. The genotype of control animals was Elav/+;Gal80ts/+ (w). ANOVA indicated significant differences in longevity between the strains (F9, 954 = 5078.6, P < 0.0001) and subsequent LSM contrast analysis indicated significant differences (P < 0.0001) in the survival of all four wt and variant Tau-expressing strains compared with controls after 20 days of We wondered whether the premature mortality of 0N4R-expressing animals could be temporally correlated with occupation of particular 'disease-associated' sites. Hence, we monitored occupation of eight such 'disease-associated' phosphoepitopes and pSer 238 and is it potentially predictive of toxicity as suggested by our Drosophila results? To investigate this possibility, we used an established mouse model (Htau mouse), which lacks endogenous Tau, but carries and expresses constitutively the entire human tau genomic locus (36) . Human Tau was detected in the hippocampi of these mice of all ages tested (Fig. 2D-Tau) . In contrast, Ser 238 phosphorylation was not detectable in 2-month-old animals, barely visible at 4 months, but unequivocally established in 8-month-old animals and highest in the oldest mice we tested, aged 15 months (Fig. 2D) . The signal was absent from control mice lacking endogenous Tau, although a faint slightly slowermigrating background band appeared in 15-month-old mice (Fig. 2D) . We are uncertain of the nature of this cross-reacting species, which has not been reported in the original and following publications (36, 37) , but it is under investigation. Nevertheless, our data indicate that as in Drosophila, occupation of Ser 238 is time-dependent and initially appears in these mice at a time characterized by mild cognitive deficits and little neuronal loss (38) . Extensive Ser 238 occupation is observed in older Htau mice, which present strong cognitive deficits and quantitative neuronal loss in their brains (39) . Therefore, the presence of phosphorylated Ser 238 characterizes toxicity linked to human Tau expressed both in Drosophila and in mice.
Ser 262 phosphorylation is required for Tau-dependent learning deficits
Limiting expression of 0N4R specifically to the adult CNS yields animals with intact MBs (15,22) , but significantly impaired olfactory learning, unlike similarly aged and treated controls (Fig. 3A) . The MBs remain morphologically normal 7 days postinduction as shown before (22) , but also in 12-and 23-day-old 0N4R-expressing animals (not shown). Significantly, expression of the S262A variant either adult-specifically (Fig. 3B) Because AT100 immunoreactivity is reduced in the S262A variant and absent from 2NS2A and RWS2A proteins whose expression does not affect learning (22), we investigated whether its occupation is essential for the learning impairment. If AT100 occupation was necessary for the learning deficit, then variants not presenting this epitope should learn normally. We focused on the T212A and S214A proteins, which lack the AT100 epitope, but retain phosphorylation at the non-mutated Ser 214 or Thr 212 , respectively ( Figs 1C and 3F ). In addition, we used S199A/T217A, which also lacks the AT100 epitope (Fig. 1C) , because it is highly phosphorylated at Thr 212 but not at Ser 214 ( Figs 1C and 3F ). All variant proteins were expressed equivalently, or higher than 0N4R ( Figs 1C and 3F ). Adult-specific expression of T212A, S214A and S199A/T217A precipitated significant learning impairments at 12 days post-eclosion ( Fig. 3C-E) , as predicted by occupation of pSer 262 (Fig. 3F) . At that time, mortality of animals expressing these variants was not different than controls (Fig. 3G) . However, by the 20th day of induction, these proteins were as toxic as 0N4R evidenced by the significant drop in survival of flies expressing them (Fig. 3G) . Therefore, AT100 occupation cannot be correlated with Tau-mediated learning deficits. In contrast, just as Ser 238 phosphorylation correlates with Tau toxicity underlying mortality, Ser 262 occupation appears predictive of that manifested as learning impairments. The effects of all variant proteins tested here with respect to Tau-mediated MB maldevelopment and learning deficits in animals with normal MBs, because of limited post-developmental CNS expression, are presented collectively in Figure 3H .
Distinct conformations characterize the toxic and dysfunctional Tau variants
Because toxicity has been linked to conformational changes (40, 41) and aggregate formation (42), we investigated these parameters for STA, S262A and wt Tau. Head lysates from animals expressing these proteins were fractionated into soluble and insoluble materials, and the latter was extracted with 70% formic acid (FA) to probe for aggregates (43) . Phosphorylationindependent antibodies revealed wt Tau, but not STA or S262A (Fig. 4A) in the insoluble fractions, suggesting that the Tau variants not associated with premature mortality do not form aggregates. Potential conformational changes were monitored with the Alz-50 and MC1 epitopes formed when discontinuous residues in the amino-terminus become proximal to the MBRs (44). This has been proposed as a distinct pathological conformation preceding aggregate formation (45) . The STA variant, which impairs learning without affecting mortality, exhibits the 'Alz50/MC1' configuration similar to wt Tau. In contrast, this conformational state was not observed in the benign variant S262A (Fig. 4B) . Collectively, these results indicate that, in the Drosophila model, premature mortality is linked to aggregate formation (0N4R and 2N4R), while the 'Alz50/MC1' conformation in the absence of aggregates (STA) appears linked to Tau-mediated learning deficits.
Ser 238 is occupied in the brain of Tauopathy patients
Is Ser 238 phosphorylated in the brain of Tauopathy patients as predicted by the data from Drosophila? To address this question, we obtained postmortem samples from clinicopathologically confirmed Tauopathy and normal (control) subjects (Table 1) . We focused on the prevalent Tauopathies, Alzheimer's (AD) and Picks Disease (PiD), typically involving hyperphosphorylation of wt Tau and frontotemporal dementia (FTD), which is associated with tau mutations (13, 46, 47) . Complete case reports including pre-mortem cognitive state and extensive post-mortem macroscopic and microscopic neuropathological examination of the brains accompanied the samples (Table 1) .
To determine whether phosphorylation of Ser 238 is associated with pathology-bearing areas of the brain, we assessed hippocampal neurons reported by the neuropathological assessment to present neurofibrillary tangles (NFTs) and neuronal loss, as well as others with little apparent damage ( Table 1) . Western blots of hippocampal tissue from AD, FTD and PiD subjects revealed the characteristic over-abundance of Tau isoforms, especially of the low mobility range compared with normal controls (Fig. 5A) . Significantly, the anti-pSer 238 antibody revealed a single reactive species, which was absent from control subjects (Fig. 5A) . The signal in the 81-year-old CN81, whose hippocampus appeared intact except for a single NFT, is consistent with potential onset of age-dependent Tau pathology, albeit asymptomatic at the time of death. Similarly, the very faint signal in CN54 may indicate potentially toxic Tau in the hippocampus, but its low abundance relative to other Tauopathy patients is consistent with the lack of histopathological or cognitive impairments (Table 1) . Furthermore, Ser 238 appeared phosphorylated in the hippocampus of subject FTD4 who did not present apparent histopathology, but this may be a difficult or misclassified case as indicated in Table 1 .
To determine whether Ser 238 was phosphorylated in brain areas reported to harbor less damage (Table 1) , we obtained superior frontal gyri (GFS) from a limited number of randomly selected subjects and compared western blots from these neurons with those from hippocampal lysates. Again, hippocampal lysates from all subjects, except the unaffected CN51, presented a highly reactive species in the 40 kDa range with the anti-pSer 238 antibody (Fig. 5B) . Apparently, the same Tau species was reactive with the AT100 and anti-pSer 262 antibodies in these samples (Fig. 5B) . These results strongly suggest that the novel antipSer 238 antibody is selective for pathogenic Tau residing in damaged areas in the brain of Tauopathy patients. Notably, the majority of phosphorylated Ser 238 resided in a band of higher molecular weight in the GFS of AD brains than the predominant phosphorylated species in PiD subjects and was absent or marginal in the FTD samples tested (Fig. 5B) . In contrast, the antibody detected a 40 kDa band in the GFS of PiD subjects, similar to that in their hippocampi (Fig. 5B) . The GFS of PiD4 did not present a strongly immunoreactive protein in agreement with the lack of obvious histopathological abnormalities ( Table 1 ). The same apparent species were immunoreactive with the AT100 and anti-pSer 262 antibodies, suggesting that they also represent hyperphosphorylated Tau. Significantly, in congruence with results from the AT100 and the anti-pSer 262 antibodies, the anti-pSer 238 signal was highly reduced in the GFS of FTD patients reported and expected to contain minimal damage (Table 1) , than the respective areas of AD and PiD patients (Fig. 5B) . The different sizes of the predominant Ser 238 -phosphorylated species in the GFS from AD and PiD subjects suggest that distinct Tau isoforms may be pathogenic in the two diseases in a tissue-specific manner. If the anti-pSer 238 antibody was specific for neurons that are damaged or harboring pathology whether clearly evident histopathologically or not (Table 1 and Fig. 5A ), then it should be selective for them in the brains of patients and not in those of healthy individuals. We selected the AT8 antibody ( pSer 202 and pThr 205 antigen) as an indicator of damaged brain areas and neurons harboring tangles because extensive data link it to AD neuropathology (48) . As expected, sections through the hippocampus of control subjects remained devoid of staining with the AT8 antibody and also when challenged with anti-pSer 238 .
In contrast, the anti-pSer 238 antibody decorated the perinuclear area of pyrsoid-appearing neurons in the hippocampi of AD subjects and smaller, rounded in appearance bodies in PiDdiagnosed individuals (Fig. 6) . AT8 was applied to adjacent sections from the same subjects as those challenged with antipSer 238 with similar if not identical results (Fig. 6) . Therefore, the anti-pSer 238 antibody is selective for damaged and tanglecontaining neurons in histological preparations as is in western blot analyses in agreement with the above-mentioned results from the Drosophila and mouse models and suggests that it could be used for diagnostic purposes. 
Discussion
The development of Tau-dependent neuropathologies requires many decades as demonstrated by the symptom onset of familial FTDP-17 late in adulthood, although the mutant Tau protein is expressed throughout the life of an affected individual (32, 49) . It is generally accepted that accumulation and eventual aggregation of hyperphosphorylated, misfolded Tau into high-molecularweight, insoluble NFTs are prerequisites for toxicity, neuronal damage and degeneration (50) (51) (52) (53) . However, a number of studies have also indicated that non-aggregated, soluble hyperphosphorylated Tau can also be toxic (54) , or linked to pathologies that may cause neuronal dysfunction without obvious degeneration (55) (56) (57) . Soluble, hyperphosphorylated Tau likely underlies synaptic dysfunction and loss in AD (55, (58) (59) (60) and in Tauopathy model systems (61, 62) , and is manifested as synaptic transmission, or learning and memory deficits without obvious degeneration (15, 36, (63) (64) (65) . Because excessively phosphorylated Tau is apparently pathogenic independent of its aggregate or soluble state, defining and understanding the role and timing of specific phosphorylations is essential in understanding the pathogenesis and progression of Tauopathies. Prior work indicated that, in the Drosophila model, particular phosphorylations mediate Tau-dependent toxicity to the developing MB neurons, but appear not to play a role in the learning deficits presented by Tau-expressing adult animals with apparently structurally normal brains (15, 22) . To elaborate upon these early results and identify phosphorylation site(s) required for Tau-mediated deficient learning, we functionally interrogated 'disease-associated phosphoepitopes' characterizing AD and other Tauopathies (13) . We avoided expression of Tau transgenes throughout development because it results in MB ablation upon expression of most Tau variants (Fig. 1B) and hence does not afford assessing the effects of Tau on learning which requires these neurons to be structurally intact (66) . Furthermore, it does not reflect the adult onset, time-dependent disease progression characteristic of Tauopathies. Finally, it does not facilitate resolution of the sought time-dependent phosphosite occupation.
In contrast, adult-specific expression revealed sequential occupation of Tau phosphorylation sites, which correlates with the Tau-dependent toxicity that leads to premature mortality. This is congruent with the time-dependent appearance of learning deficits of Tau-expressing animals described before (22) . Our data clearly demonstrate that hyperphosphorylation is not toxic per se because although phosphorylation of the STA variant is extensive and elevated on all sites tested ( Supplementary  Material, Fig. S4A ), accumulation of this variant is not toxic to (15), or to the post-developmental adult CNS, indicated by the normal lifespan of these flies (Fig. 2B) . In agreement, hyperphosphorylation is known to occur normally during fetal brain development (67) and hibernation (68) without apparent neuronal damage. Congruent with evidence from in vitro experiments or tissue culture models (29, 69) , our results strongly suggest that Tau phosphorylation is a sequential process. Immediately following the appearance of Tau in adult brains, we detect epitopes present both in human AD and control subjects such as AT8, pThr 212 , pSer 396 and pSer 404 (12) . This is followed by occupation of Ser 214 , Ser 262 and Ser 238 , which are also occupied exclusively in Tauopathy brains ( Fig.5 and (8)). Delayed phosphorylation of Ser 214 ( Fig. 2A) , which is essential for epitope recognition, accounts for the lag in AT100 detection in the fly CNS as also reported for 0N4R expressed in adult Drosophila glia (34) , which are blocked in 2NS2A, are involved in the proposed permissive conformational changes in agreement with a prior proposal (27) . Roles consistent with local conformation-driven regulation of Tau phosphorylation have been proposed for additional sites (71) (72) (73) and may underlie a putative transition from neuronal dysfunction-mediating toxicity to overt degeneration and neuronal loss in animal models and Tauopathy patients.
Our results provide further credence to the hypothesis that occupation of specific sites mediates the transition from toxicity underlying deficient learning to lethality, by identification of two such 'gatekeeper' phosphorylations. Phosphorylation at Ser 262 is critical for learning deficit-manifested Tau toxicity in adult Drosophila and consistently, it is present in the brains of Tauopathy patients, but not of control subjects (Fig. 5) . In support of this conclusion, Ser 262 is occupied expediently in the STA mutant, which we show to be associated with Tau-dependent learning impairment, but not premature lethality in Drosophila. Significantly, we also identify the novel late-appearing phosphorylation on Ser 238 as critical for Tau-dependent premature mortality in the adult fly and the Htau mouse Tauopathy models. Ser
238
-phosphorylated wt Tau isoforms form aggregates. Importantly, these are eliminated by directly blocking this site by mutating this Ser to Ala (STA), or indirectly by a similar mutation of the preceding 'gatekeeper' phospho-site Ser 262 (Fig. 4A) . Since blockade of these phosphorylations eliminates aggregates and premature mortality, we suggest that Tau aggregation in Drosophila requires Ser 262 -dependent Ser 238 occupation and this seems to be reflected in the hippocampi of Tauopathy patients where both of these sites are occupied and absent from control subjects (Fig. 5B) . Moreover, the pSer 238 epitope is present in brain areas of Tauopathy patients presenting damage, NFTs and neuronal loss ( Fig. 5A and B) , decorating neurons appearing to harbor tangles (Fig. 6 ). Given the time-dependent appearance of this epitope in the fly and mouse models and its close association with lethality in the flies, the data suggest that Ser 238 occupation may also be linked with Tau-dependent neuronal loss in humans. Because Ser 238 phosphorylation is characteristically absent from all nontoxic Tau variants tested in Drosophila, young unsymptomatic Htau mice (36) and human control subjects (Fig. 5) , the epitope could constitute a specific diagnostic tool for late-stage Tauopathies.
The delayed occupation of Ser 238 and its dependence on prior phosphorylation of Ser 262 (Fig. 1C) is also consistent with the notion that conformational changes are required for occupation of both sites. Moreover, it appears that occupation of Ser 262 is required for Tau to assume the 'Alz 50' conformation, which is present in the STA variant that does not affect lifespan, but precipitates neuronal dysfunction (Fig. 4B) . Therefore, we suggest that the 'Alz50' Tau conformation may precede aggregate formation and could be linked to deficient learning, but not mortality. Significantly, as predicted by the apparent importance of Ser 262 phosphorylation, blocking it limits both AT100 and pSer 238 occupation ( Fig. 1C and E ) and eliminates the Tau-dependent premature mortality (Fig. 2B ). Although our evidence suggests that appearance of the AT100 epitope is not linked to learning deficits in the fly model, it represents a useful temporal marker of Tau pathogenicity both in the fly and humans (Fig. 5B) , at least inasmuch as its appearance precedes Ser 238 phosphorylation ( Fig. 2A) . is involved in maintaining basal Τau phosphorylation or suppressing hyperphosphorylation at distant sites including the 'disease-specific' epitopes we tested. This is consistent with the constitutive Thr 245 occupation in Tau from normal brains (23) (24) (25) , and this hypothesis is the subject of ongoing work. Collectively, our data indicate that the sequential phosphorylation at Ser 262 followed by Ser 238 in Drosophila may reflect the potentially increasing Tau toxicity, which may underlie the escalating symptom severity in Tauopathy patients from the initial cognitive deficits to neurodegeneration. The mechanisms mediating sequential phosphorylation at these critical sites, the likely distinct processes precipitating cognitive deficits and neurotoxicity and their potential applications to Tauopathy diagnosis and treatment, are of particular interest and the focus of future work.
Materials and Methods

Drosophila culture and strains
Flies were cultured as described before (74) . Elav C155 -Gal4 (75) was used for pan-neuronal transgene expression, whereas Elav C155 -Gal4; tubGal80 ts was used for conditional expression (15 
Transgenic mice
Transgenic mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Htau mice are homozygous for a targeted knockout of endogenous Tau, but also carry a 200-250 kb transgene containing the entire human Tau locus (36, 39) . Mice were bred and maintained in the animal facilities of BSRC 'Alexander Fleming' under pathogen-free conditions. Mice were sacrificed by carbon dioxide asphyxiation followed by immediate removal and homogenization of their hippocampi.
Human brain tissue
Frozen autopsied hippocampi and GFS were obtained from The Netherlands Brain Bank (NBB), Netherlands Institute for Neuroscience, Amsterdam. The ages, gender, Braak stages, tangle scores and diagnosis of these samples are listed in Table 1 . Samples were prepared and run as described (76) in Biorad 8-16% precast gradient gels.
Western blotting and antibodies
Total Tau levels and phosphorylation status were determined in 4.5 adult female head homogenates in 1× Laemmli buffer unless indicated otherwise. Monoclonal antibodies used were T46 (Invitrogen, 1 : 3000), AT100 (Pierce Endogen, 1 : 250), AT8 (1 : 200) and the polyclonal antibodies pS262, pS396 and pS404 (ProSci) at 1 : 1000. Alz50 and MC1 antibodies were provided by P. Davies and used at 1 : 100. Anti-syntaxin (mAb 8C3, Developmental Studies Hybridoma Bank, 1 : 3000) was used to normalize sample loading. Secondary antibodies were applied at 1 : 5000. The human Tau phospho-Ser 238 antibody was raised against peptide TPPKSPSpSAKSRLQTAPVPMP, and hybridomas were identified by the EMBL Monoclonal Antibody Core Facility (Monterotondo, Italy). Culture supernatant was used at 1 : 10. Extraction of soluble and insoluble proteins and immunoblot analysis were performed as described (43) .
Histology
Immunohistochemistry on Drosophila head frontal paraffin sections was performed as previously described (77) using anti-Leo at 1 : 4000. For immunohistochemistry on human hippocampal brain tissue obtained from NBB, 8 μm formalin-fixed paraffin-embedded sections were de-paraffinized in xylene, rehydrated and boiled for 10 min in TBS (0.05 M TBS, 0.05% Tween 20, pH 9.0) for antigen retrieval. Subsequently, all sections were washed with 0.1 M PBS pH 7.4 and incubated for 3 h at room temperature in 2% BSA and 0.25% Tween-20 in PBS to block nonspecific binding. All primary antibodies, diluted in PBS containing 0.25% Tween-20 and 1% BSA, were applied to sections and then incubated overnight at 4°C (AT8 1 : 500 and pS238 1 : 100 dilution). The sections were then incubated with the biotinylated anti-mouse secondary antibody (1 : 2000; Vector Laboratories, Burlingame, CA, USA) for 2 h at room temperature followed by incubation in streptavidin ABC (Vectastain Elite ABC Kit; Vector Laboratories). Slides were developed using diaminobenzidine and counterstained with hematoxylin. Sections were dehydrated through double distilled water, graded ethanol and washed twice in xylene. All sections were mounted in DPX-mounting medium under a glass coverslip.
Lifespan determination
Animals accumulating Tau protein variants under Elav C155 -Gal4; tubGal80 ts were raised at 18°C together with control heterozygotes and subsequently at least four vials of 20, 1-to 3-day-old males per genotype were maintained at 30°C transferring to fresh vials every 3 days until they expired. The entire experiment was repeated three times independently and the results pooled such that at least 300 flies were assessed per genotype.
Behavioral analyses
Olfactory learning coupling aversive odors (conditioned stimuli) with electric shocks (unconditioned stimulus) was performed as described (15) . Briefly, flies held at 30°C for the indicated times were allowed to acclimate to the 25°C training temperature for 15 min. They were then conditioned with eight 90 Volt DC electric shocks delivered in the presence of the aversive odor 3-octanol for 40 s, followed by a 30-s rest and then exposure for 40 s to the unpaired odorant benzaldehyde. Another group of animals were trained simultaneously, where benzaldehyde was paired to shock and 3-octanol was used as the control unpaired odorant. Three minutes after conditioning, both groups of flies were tested simultaneously for preferential avoidance of the conditioned odorant. The fraction of flies avoiding each conditioned odorant was calculated, and the average score for each simultaneously and complementary trained group was calculated and reported as the performance index. All genotypes in a particular graph were run in the same day and each entire experiment (n > 8 per genotype) was repeated at least twice.
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Animals were kept under specific pathogen free conditions and were sacrificed as described in approved protocols by the Prefecture of Eastern Attica, Directorate General of Veterinary Services, Animal Health Directorate (License No. 429-EL09BIO05). Human tissues obtained from NBB, Netherlands Institute for Neuroscience, Amsterdam, were used as per MTA 457.13. All materials have been collected from donors, from whom a written informed consent for a brain autopsy and the use of the material and clinical information for research purposes had been obtained by the NBB.
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